Back to Research Home
ELVElevance Health Inc
Health Care · Managed Health Care · Large
$439.95−1.20%
As of 23 Oct 2026Mkt cap $88.0B
Stage 13
AVOID
Fundamentals
35.6/75
Technical
6.0/15
Independent
41.6/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +10.5%
- 3M
- +16.3%
- 6M
- +27.6%
- 1Y
- +27.4%
Financials & valuation
Cached filing evidence · as of 2026-10-21
Valuation
- P/E
- 18.8xHist median 15.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 15.2x
- FCF yield
- 6.6%
Quality
- ROIC
- 9.2%
- Operating margin
- 4.4%
- FCF margin
- 1.6%
- Current ratio
- 1.5x
Growth
- Revenue growth
- +12.5%Latest FY YoY
- Revenue CAGR
- +9.5%
- EPS CAGR
- +0.3%
- FCF CAGR
- −18.7%
Capital
- Share-count trend
- −2.7%3Y annualised
- Net debt
- $23.2B5.4x OCF
Annual trend
- CAGR 2021–2025
- +9.5%
- Latest · 2025
- $199B
- YoY
- +12.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-28
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-21
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded